Triazole refers to a heterocyclic compound with the molecular formula C2H3N3, which has a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease already affect many people around the world, and these numbers are increasing rapidly. Treatment for these disorders is often aimed at relieving symptoms and has no cure. Research on new molecules is underway, and heterocyclic compounds have important pharmacological implications. Triazoles and tetrazoles are emerging as new molecules in this field.
SGR-1505 is an investigational mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor developed by Schrödinger. MALT1 is a key mediator of the NF-κB signaling pathway and the main driver of a subset of B-cell lymphomas. Over eight billion compound designs were assessed using Schrödinger’s in-house computational MPO chemistry suite, of which only 129 were synthesized. SGR-1505 demonstrated preclinical single-agent and combination activity in B cell malignancies and showed the ability to resensitize drug-resistant tumors to BTK and BCL-2 inhibitors. The compound has completed Ph. I studies in healthy volunteers and has progressed into a Ph. I trial in patients with mature B cell malignancies. Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Search 
+86 21 5895 0110 
